Lybrido, an oral tablet from Freya Pharma Solutions, will enter Phase III studies to treat female sexual interest/arousal issue (FSIAD) after being in development for almost a decade. The EMA provided scientific guidance to the firm on the planned Phase III study, which will be followed by subsequent trials in Europe and the US, the company informs. Freya’s chief medical officer (CMO) says that at the end of this year or the beginning of 2023, the company intends to file a request for advice from the FDA.
Read More from Pharmaceutical-Technology
English